Editas Medicine (EDIT) Prices 3.5M Share Common Offering at $66/Sh

Pre-Open Stock Movers 01/20: (APM) (EVLO) (NFLX) Higher; (GEVO) (HSTO) (BLRX) Lower (more...)

Pre-Open Stock Movers:

Aptorum Group Limited (NASDAQ: APM) 42.8% HIGHER; announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA.

Gevo (NASDAQ: GEVO) 21.6% LOWER; announced that it has entered into definitive agreements... More

After-Hours Stock Movers 01/19: (NFLX) (CKPT) (PCAR) Higher; (HSTO) (BLRX) (ACRX) Lower (more...)

After-Hours Stock Movers:

Histogen Inc. (NASDAQ: HSTO) 16.5% LOWER; announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that it has additional questions about the companys Investigational New Drug (IND) application package for the planned Phase 1/2 clinical trial of HST-003, which is intended to evaluate the safety and efficacy of human extracellular matrix (hECM:HST-003) implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.

BioLineRx Ltd. (NASDAQ:... More

Editas Medicine (EDIT) Announces 3.5M Share Offering of Common Stock

Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an... More

Pre-Open Stock Movers 01/19: (ACRS) (GEVO) (GM) Higher; (PRPH) (EDIT) (MGI) Lower (more...)

Pre-Open Stock Movers:

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) 128.4% HIGHER; announced positive preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo-controlled clinical trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (RA) (ATI-450-RA-201). ATI-450 was developed internally utilizing Aclaris proprietary KINect drug discovery platform.

Gritstone Oncology, Inc. (NASDAQ: GRTS) 46.2% HIGHER; today announced that it... More

Editas Medicine (EDIT) IV at 122 amid wide price movement

Editas Medicine (NASDAQ: EDIT) 30-day option implied volatility is at 122; compared to its 52-week range of 61 to 152.

Morgan Stanley Downgrades Editas Medicine (EDIT) to Underweight

Morgan Stanley analyst Matthew Harrison downgraded Editas Medicine (NASDAQ: EDIT) from Equalweight to Underweight with a price target of $45.00.

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $76.14 yesterday.